Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...

A report from The Lancet Diabetes & Endocrinology Commission has proposed new criteria for defining and diagnosing obesity, ...

A Medscape survey found that a strong majority of physicians believe high-risk patients should have easier access to new weight loss drugs.

The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide ...

New Rule Seeks to Expand Medicare and Medicaid Coverage of Weight Loss Drugs. The Biden Administration has proposed a new ...

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will ...

The Biden administration said Medicare will negotiate discounts with drug companies on 15 drugs prescribed to treat cancer, ...

The directive for the Department of Health and Human Services to develop and test new models aimed at lowering drug costs ...

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the ...

Will Medicare end Novo Nordisk's obesity drug boom? It's not surprising that CMS chose Ozempic, Wegovy, and Rybelsus for Medicare drug price negotiations. Between November 2023 and October 2024 ...

Diabetes and weight loss drugs Ozempic and Wegovy have been added to the list of medications selected for Medicare price ...